Radiopharmaceuticals, a unique intersection of nuclear medicine and pharmacology, have revolutionized the diagnosis and treatment of various diseases, particularly cancers. These compounds, labeled with radioactive isotopes, serve as diagnostic agents and therapeutic tools. The escalating

Radiopharmaceuticals lie at the forefront of nuclear medicine, bridging the gap between molecular targeting and therapeutic intervention. These compounds, infused with radioactive isotopes, are designed to treat and diagnose diseases, principally cancer. As the field evolves, the need to